1.0Lanco Medical Grouphttps://lancomedicalgroup.com/eslmgrouphttps://lancomedicalgroup.com/es/author/lmgroup/rich600338<blockquote class="wp-embedded-content" data-secret="0EEqJ6QMbt"><a href="https://lancomedicalgroup.com/es/lmg/">ametralladora ligera</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://lancomedicalgroup.com/es/lmg/embed/#?secret=0EEqJ6QMbt" width="600" height="338" title="«LMG» — Lanco Medical Group" data-secret="0EEqJ6QMbt" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://lancomedicalgroup.com/wp-includes/js/wp-embed.min.js </script>PORTAFOLIO ACCESO PAÍSES NOSOTROS CONTACTO Local presence. Regional impact The partner that turns portfolio into results 12 years of specialized pharma operations across Central America & the Caribbean. High-value portfolio. Direct institutional access. One regional operating partner. +12 Years in Operation 6 Active Countries 144M+ Units 2025 69% Institutional Channel Your current portfolio has a ceiling You the institutional market doesn’t The Problem Low-margin generics — Most local distributors compete in the same generics segment where margins shrink every year. Without biosimilars or specialty molecules, growth is structurally limited. Institutional tenders out of reach — CSS, CCSS, IGSS, IHSS, ISSS, and SeNaSa represent 60%+ of the regional market. Winning tenders requires relationships, track record, and capacity that most distributors can’t access alone. RTCA registrations: time and cost out of control — Registering in 6 countries requires specialized teams, 18–36 month timelines, and regulatory investment most distributors can’t carry without the manufacturer. Our 3 Pillars Access to high-value specialty molecules: biosimilars, biologics, anticoagulants, oncology, neurology, cardiovascular, and next-generation diabetes therapies. Portfolio without exclusivity conflicts. Biosimilars and Biologics · Anticoagulants — leaders in hemophilia in Costa Rica · Oncology · Cardiovascular · Neurology and Antiepileptics · Second-Generation Diabetes CTD dossiers for generics, biosimilars, and biologics under the RTCA framework. 83–100 point checklists per country. Active registrations maintained. We have never lost a file to a procedural error. The Problem Our 3 Pillars Specialized portfolio by therapeutic area Anticoagulants and Hematology Leaders in hemophilia treatment in Costa Rica. Portfolio with active registrations across all 6 countries. Direct institutional channel with CCSS, IGSS, and CSS. Oncology and Biosimilars Access to biosimilars from reference international manufacturers. Biological dossier management under RTCA. Experience in institutional oncology tenders. Cardiovascular Angiotensin inhibitors, calcium channel blockers, and antihypertensive agents. Active public and private channel across all 6 countries. Diabetes and Metabolism Second-generation hypoglycemic agents. Priority institutional access in chronic disease plans at CSS, CCSS, and IGSS. Neurology Antiepileptics with active registrations across the region. Experience in hospital-use protocols and chronic patient management. High Specialty and Biologicals Biologics from tier-1 international manufacturers. Cold chain management, special-use protocols, and patient follow-up. The fastest-growing segment in the region. Results that speak for themselves. +12 Years in Operation 6 Active Countries 144M+ Units 2025 69% Institutional Channel 2021 Distributor of the Year (USA 2022 Largest CCSS Contract 2022 Happy Workers Award Panama 2023 Entrepreneur of the Year (USA) 2023 Leaders in Hemophilia — Costa Rica Where we operate. How we operate Direct presence — not external agents Guatemala IGSS · Instituto Guatemalteco de Seguridad Social Fastest-growing market in our specialty portfolio. Honduras IHSS · Instituto Hondureño de Seguridad Social Active institutional access. Specialized local sales force. Dominican Republic SeNaSa · Seguro Nacional de Salud High-potential Caribbean market. Active institutional expansion. El Salvador ISSS · Instituto Salvadoreño del Seguro Social Institutional and private pharmacy channel. Sustained growth. Costa Rica CCSS · Caja Costarricense de Seguro Social Our largest contract to date. Leaders in Hemophilia treatment. Panama CSS · Caja de Seguro Social Public and private institutional channel. Regional operational hub. We are Lanco Medical Group With 12 years of operations across Central America and the Caribbean, we’ve built what most distributors spend years trying to build: direct relationships with the region’s most important public health institutions, a team specialized by therapeutic area, and the regulatory infrastructure to register and maintain complex products. We are not a generic distribution intermediary. We are the specialized operator that turns a high-value portfolio into institutional channel results. 144 million units consumed in 2025 are not a statistic — they are patients served. Part of the LMG Bio Lifesciences ecosystem — the strategic platform connecting global pharma with Latin America. I’m a local distributor Ready to expand your portfolio with high-value specialty molecules? Which molecules in our portfolio are compatible with your current distribution network How joint institutional access works — tenders you can win with our backing What RTCA regulatory support is included at no extra cost Real margins — a structure designed for the distributor to win No generic proposals. No commitments before understanding your operation. I’m an international manufacturer Ready to expand your portfolio with high-value specialty molecules? Our active distribution network by country — contacts, sales history, institutions served Active RTCA registrations in our current portfolio — direct evidence of regulatory capacity Institutional tender track record — including the largest CCSS contract in our therapeutic area What the operational entry of your molecule would look like — timeline, responsibilities, regulatory investment This isn’t a pitch. It’s a technical review of capabilities. Let’s Talk JUNTOS, SÍ HACEMOS SALUD Lanco Medical Group · info@lancomedicalgroup.com · www.lancomedicalgroup.com Panamá · Costa Rica · Guatemala · Honduras · El Salvador · República Dominicana © 2 0 2 6 L a n c o M e d i c a l G r o u p . To d o s l o s d e r e c h o s r e s e r v a d o s .https://lancomedicalgroup.com/wp-content/uploads/2026/04/LMG-blanco.png720390